![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 09, 2019 1:19:08 PM
It’s exactly how they are paying the university for clinical trials. Everything is now in place and imo this is ready to fly!!! There is nothing on the market that kills cancer like Adva-27a.
The manufacturing of Adva-27a has all been taken care of....
Kaboom Baby.
Crocus validated the relationship through this email today....
“Crocus signed a confidentiality agreement with Sunshine Biopharma. Hence, I
do not feel comfortable to discuss the matter.
Please, contact Sunshine Biopharma.
Best regards”
For Immediate Release December 12, 2018
SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG
Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine’s lead anticancer compound targeted for Pancreatic Cancer. The material which will ultimately be generated by a contract manufacturing organization will be used for animal toxicity studies and clinical trials.
About Crocus Laboratories Inc.
Crocus Laboratories Inc. is a Canadian medicinal chemistry company engaged in the design and synthesis of new chemical entities, including enzyme inhibitors, receptor modulators and compound libraries. The Crocus team has extensive experience in drug discovery and development, particularly in the areas of oncology and infectious diseases. More information about Crocus is available at www.crocuslaboratories.com.
About Sunshine Biopharma’s Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Recent SBFM News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 07/11/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:05:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/05/2024 09:37:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/23/2024 09:03:01 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/21/2024 09:28:39 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/21/2024 01:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 04:39:32 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:53:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/14/2024 04:18:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:04:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:17:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:17:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 05:38:24 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2024 01:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:59:51 PM
- Sunshine Biopharma Moves Principal Office to New York City • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 04:18:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/20/2023 05:06:33 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM